HT-0712

HT-0712

Systematic (IUPAC) name
(3S,5S)-5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one
Identifiers
CAS Number	617720-02-2
PubChem	CID: 9865375
ChemSpider	8041067 Y
Synonyms	HT-0712, IPL 455,903
Chemical data
Formula	C25H31NO3
Molecular mass	393.53 g/mol
SMILES O=C3NC[C@H](c2cc(OC1CCCC1)c(OC)cc2)C[C@H]3Cc4cccc(c4)C
InChI InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1 Y Key:ABEJDMOBAFLQNJ-NHCUHLMSSA-N Y
(verify)

HT-0712 also known as IPL-455903, is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.

Mechanism of action

HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.

The side effects of the drug are not yet fully known.

Research

A 2014 study found that HT-0712 significantly boosted memory formation in mice. Data also indicated that HT-0712 may be effective to treat age-associated memory impairment in humans.

External links

• United States Patent 20040224316
• PDF file regarding Helicon's commencement of Phase I trials